30th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100190641 | Method for manufacture of noble metal alloy catalysts and catalysts prepared therewith - The present invention provides a method for manufacture of supported noble metal based alloy catalysts with a high degree of alloying and a small crystallite size. The method is based on the use of polyol solvents as reaction medium and comprises of a two-step reduction process in the presence of a support material. In the first step, the first metal (M1 =transition metal; e.g. Co, Cr, Ru) is activated by increasing the reaction temperature to 80 to 160° C. In the second step, the second metal (M2=noble metal; e.g. Pt, Pd, Au and mixtures thereof) is added and the slurry is heated to the boiling point of the polyol solvent in a range of 160 to 300° C. Due to this two-step method, an uniform reduction occurs, resulting in noble metal based catalysts with a high degree of alloying and a small crystallite size of less than 3 nm. Due to the high degree of alloying, the lattice constants are lowered. The catalysts manufactured according to the method are used as electrocatalysts for polymer electrolyte membrane fuel cells (PEMFC), direct-methanol fuel cells (DMFC) or as gas phase catalysts for CO oxidation or exhaust gas purification. | 2010-07-29 |
20100190642 | Catalyst for Decomposition of Nitrogen Oxides - This invention relates generally to a platinized tin oxide-based catalyst. It relates particularly to an improved platinized tin oxide-based catalyst able to decompose nitric oxide to nitrogen and oxygen without the necessity of a reducing gas. | 2010-07-29 |
20100190643 | DEACTIVATION RESISTANT PHOTOCATALYST AND METHOD OF PREPARATION - A photocatalyst formed using a sol-gel process provides high photo activity, increased photocatalyst lifetime, and improved resistance to performance degradation caused by siloxane-based contaminants. The photocatalyst comprises particles of photocatalytically-active oxide having a surface area of greater than about 190 m | 2010-07-29 |
20100190644 | HEAT SENSITIVE RECORDING MATERIAL COMPRISING A PROTECTIVE LAYER - A heat-sensitive recording material comprises a support, a heat-sensitive recording layer including a leuco dye and a developer, and a protective layer comprising a pigment and a binder. The heat-sensitive recording layer is located between the support and the protective layer. The pigment in the protective layer comprises secondary particles with an average particle diameter of about 30 to 900 nm formed preferably by aggregation of amorphous silica primary particles with a particle diameter of about 3 to 70 nm. The secondary particles are present in a proportion of about 5 to 35 mass % relative to total solids of the protective layer. The colloidal silica is present in a proportion of about 1 to 25 mass % relative to total solids of the protective layer. | 2010-07-29 |
20100190645 | SYNERGISTIC FUNGICIDAL ACTIVE COMPOUND COMBINATIONS COMPRISING FORMONONETIN - Novel active compound combinations comprising formononetin of formula (I) | 2010-07-29 |
20100190646 | Fungicidal Mixtures of Triticonazole and Difenoconazole - Fungicidal mixtures comprising, as active components: | 2010-07-29 |
20100190647 | Method for improved utilization of the production potential of transgenic plants introduction - The Invention discloses novel uses and methods for 3-APD directed to increasing the production potential of transgenic plants as well as methods for controlling unwanted animal pests on transgenic plants by application of the compounds to the transgenic plants or to propagation material of these plants. | 2010-07-29 |
20100190648 | Structured Agrochemical Oil Based Systems - Structured agrochemical concentrates comprise agrochemical actives dispersed in a structured oil system of an oil and structurant oligomer including urethane and/or urea linkages and residues of a dimer or trimer component. The concentrate formulations may contain other components such as surfactants without the structurant loosing its effect a problem with known structurants. The concentrates can be readily diluted to give sprayable agrochemical formulations. | 2010-07-29 |
20100190649 | LOW LOSS JOINT FOR SUPERCONDUCTING WIRE - A device and method for making a persistent joint allowing end terminations of superconducting MgB | 2010-07-29 |
20100190650 | TRANSCRIPTOMIC BIOMARKER OF MYOCARDITIS - Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified. | 2010-07-29 |
20100190651 | METHOD OF ANALYZING PROBE NUCLEIC ACID, MICROARRAY AND KIT FOR THE SAME - Provided are a method of analyzing a sequence of a first probe nucleic acid using a substrate on which a second probe nucleic acid is immobilized, and a microarray and a kit for the same. | 2010-07-29 |
20100190652 | Biomarkers for Detection of Neonatal Sepsis in Biological Fluid - The present invention concerns the identification and detection of biological fluid biomarkers of neonatal sepsis using global proteomic approaches. | 2010-07-29 |
20100190653 | Nucleotide sequences encoding alanine racemase from coryneform - The invention relates to an isolated polynucleotide having a polynucleotide sequence which codes for the alr gene, and a host-vector system having a coryneform host bacterium in which the alr gene is present in attenuated form and a vector which carries at least the alr gene according to SEQ ID No 1, and the use of polynucleotides which comprise the sequences according to the invention as hybridization probes. | 2010-07-29 |
20100190654 | NANOARRAYS AND METHODS AND MATERIALS FOR FABRICATING SAME - A nanoarray includes a fluoropolymer array defining a plurality of cavities where each cavity has a predetermined shape and is less than about 5 micrometers in a broadest cross-sectional dimension. The nanoarray also includes a composition discretely contained in each cavity, where the composition includes a linking group for coupling with a modifying group. The nanoarray can be fabricated from fluoropolyether or perfluoropolyether. | 2010-07-29 |
20100190655 | FUSION POLYPEPTIDE FOR DETECTION OF CONSERVED COMBINATORIAL OR COMPOSITE EPITOPES IN NON-CONSERVED PROTEINS - The present invention provides multiepitope-binding fusion polypeptides for use in a method for the detection of the presence of human immunodeficiency virus, HIV, in a biological sample. The present invention also provides a method for producing multiepitope-binding fusion polypeptides. | 2010-07-29 |
20100190656 | Breast Cancer Specific Markers and Methods of Use - The present invention relates to breast cancer biomarkers useful for the detection, diagnosis and therapeutic treatment of breast cancer. | 2010-07-29 |
20100190657 | Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization - Methods for assaying a sample for a probe polynucleotide are provided. The methods comprise forming a complex between a target on a substrate, the probe polynucleotide that binds to the target, and a conjugate comprising a semiconductor nanocrystal that binds to the probe polynucleotide by way of a tag sequence on the probe polynucleotide. The complex is formed when the probe polynucleotide is present in the sample. The methods are useful in any technique in which the detection of a target that can bind to a probe polynucleotide is desired, for example in fluorescence in situ hybridization. The methods are particularly useful in multiplex settings such as hybridization to microarrays where a plurality of targets are present. Assay complexes produced by such methods and kits useful for performing such methods are also provided. | 2010-07-29 |
20100190658 | COLORIMETRIC ASSAY FOR THE VISUAL DETECTION OF PRIMARY AND SECONDARY AMINES - The present invention concerns a novel method and kit system for the detection of solid-phase bound primary amines, secondary amines, or thiol groups comprising adding a fluid to said substrate and further comprising adding a novel reagents to said substrate and recording a colour reaction on said substrate that comprise said amine or said thiol groups. The method and kit of present invention can be used for the quantitative determination of organic substituents with primary or secondary amines or with thiol groups immobilized on or in insoluble materials. | 2010-07-29 |
20100190659 | Compositions and Methods for Diagnosing and Assessing Inflammatory Myopathies - The present invention is directed to assay methods for inflammatory myopathies and microarray plates that can be used in carrying out these assays. | 2010-07-29 |
20100190660 | Methods, Compositions And Libraries Pertaining To PNA Dimer And PNA Oligomer Synthesis - This invention pertains to the field of PNA dimer and PNA oligomer synthesis. | 2010-07-29 |
20100190661 | SERS-ACTIVE STRUCTURE FOR USE IN RAMAN SPECTROSCOPY - A surface-enhanced Raman spectroscopy (SERS)—active structure for use in Raman scattering detection has an array of nanostructures formed on a substrate by deposition and chemical etching. The nanostructures are coated with metal nanoparticles. | 2010-07-29 |
20100190662 | METHODS AND MATERIALS FOR DETECTION, DIAGNOSIS AND MANAGEMENT OF OVARIAN CANCER - The subject invention concerns methods using a panel of proteins to detect, diagnose, and monitor therapy during treatment of ovarian cancer in a female patient. The proteins were identified using proteomics analyses of plasma samples obtained preoperatively from ovarian cancer patients versus those of healthy control women. Such a panel has utility for the diagnosis of ovarian cancer, screening for ovarian cancer and possibly therapeutic monitoring. | 2010-07-29 |
20100190663 | DEVICE FOR WASHING AND HYBRIDIZATION OF BIOCHIPS - A device for biochip hybridization or washing is provided, which comprises a carousel ( | 2010-07-29 |
20100190664 | INVERT EMULSION BASED COMPLETION AND DISPLACEMENT FLUID AND METHOD OF USE - A method of cleaning a wellbore prior to the production of oil or gas, wherein the wellbore has been drilled with an invert emulsion drilling mud that forms an invert emulsion filter cake is disclosed. The method may include circulating a breaker fluid into the wellbore, where the breaker fluid includes a non-oleaginous internal phase and an oleaginous external phase, where the non-oleaginous phase includes a water soluble polar organic solvent, a hydrolysable ester of a carboxylic acid, and a weighting agent, and the oleaginous external phase includes an oleaginous fluid and an emulsifier, and where the hydrolysable ester is selected so that upon hydrolysis an organic acid is released and the invert emulsion of the filter cake breaks. | 2010-07-29 |
20100190665 | FLUID AND METHOD FOR AGGLOMERATING PARTICLES IN A WELL SERVICE OPERATION - Flocculants and/or coagulants are used with recyclable drilling fluids to agglomerate particles and in particular fine solids (“fines”) including coal fines, such that they settle out of the fluid. The most widely used flocculants are different types of polymers including polyacrylamide (PMA) having different molecular weights, polyethylene oxide (PEO) having various molecular weights and other suitable polymeric flocculents known in coal beneficiation industry. For coal fines, other coagulants such as hydrocarbons, including kerosene, fuel oil, or a C | 2010-07-29 |
20100190666 | METHOD FOR TREATING FRACTURING WATER - A method of treating a medium for water fracturing is disclosed, the method comprises: introducing at least one biocide and at least one metabolic inhibitor in the medium, using the medium for water fracturing. In another aspect a method of controlling the post-fracture reservoir souring by the metabolic activities of sulfate reducing bacteria of a well is described: at least one biocide and at least one metabolic inhibitor are introduced in a medium made of water, the medium is used for fracturing the well, and the medium remains in the reservoir to kill and/or inhibit growth of sulfate reducing bacteria. | 2010-07-29 |
20100190667 | LEAD-FREE SINTERED LUBRICATING MATERIAL AND SINTER POWDER FOR MANUFACTURE OF THE SAME - The invention relates to a lead-free sliding bearing material having a Cu-based or CuSn-based sintered matrix and a solid lubricant. The solid lubricant contains hexagonal boron nitride in a fine-grained distribution with a mean particle size of 10 μm or less, wherein agglomerates of the particles of hexagonal boron nitride are not greater than 200 μm. The invention also relates to a sintering powder for producing the sliding bearing material, a sliding bearing composite material having a steel protective layer and a bearing layer composed of such a sintered-on sliding bearing material. The invention also relates to a sliding element composed of a sliding bearing composite material of the type mentioned above. | 2010-07-29 |
20100190668 | Grease Composition and Process for Producing the Same - A process for producing a grease composition which is capable of homogeneously and surely dispersing a non-fluorine-based base oil blended with a thickening agent and a fluorine-based base oil blended with a thickening agent. A mixture of a non-fluorine-based base oil blended with a first thickening agent and a fluorine-based base oil blended with a second thickening agent that are not mutually compatible is homogeneously treated at a shear rate of 150 s | 2010-07-29 |
20100190669 | Method of Lubricating an Aluminum Silicate Composite Surface with a Lubricant Comprising Ashless, Sulphur, Phosphorous Free Antiwear Agent - The present invention relates to a method of lubricating an aluminium-composite surface by supplying to the aluminium composite surface (typically an internal combustion engine aluminium surface) a lubricating composition comprising an oil of lubricating viscosity and an ashless antiwear agent. | 2010-07-29 |
20100190670 | LUBRICANT ADDITIVE AND LUBRICANT COMPOSITION - A lubricating oil additive contains at least one steroid derivative selected from steroid saturated fatty acid ester, steroid carbonate ester and steroid ether. A lubricating oil composition added with the lubricating oil additive exhibits a low friction coefficient and excellent wear resistance, heat resistance and oxidation resistance stability. | 2010-07-29 |
20100190671 | USE OF COMB POLYMERS FOR REDUCING FUEL CONSUMPTION - The present invention relates to the use of comb polymers comprising, in the main chain, repeat units which are derived from polyolefin-based macromonomers, and repeat units which are derived from low molecular weight monomers selected from the group consisting of styrene monomers having 8 to 17 carbon atoms, alkyl (meth)acrylates having 1 to 10 carbon atoms in the alcohol group, vinyl esters having 1 to 11 carbon atoms in the acyl group, vinyl ethers having 1 to 10 carbon atoms in the alcohol group, (di)alkyl fumarates having 1 to 10 carbon atoms in the alcohol group, (di)alkyl maleates having 1 to 10 carbon atoms in the alcohol group and mixtures of these monomers, where the molar degree of branching is in the range of 0.1 to 10 mol % and the comb polymer comprises a total of at least 80% by weight, based on the weight of the repeat units, of repeat units which are derived from polyolefin-based macromonomers and repeat units which are derived from low molecular weight monomers selected from the group consisting of styrene monomers having 8 to 17 carbon atoms, alkyl (meth)acrylates having 1 to 10 carbon atoms in the alcohol group, vinyl esters having 1 to 11 carbon atoms in the acyl group, vinyl ethers having 1 to 10 carbon atoms in the alcohol group, (di)alkyl fumarates having 1 to 10 carbon atoms in the alcohol group, (di)alkyl maleates having 1 to 10 carbon atoms in the alcohol group and mixtures of these monomers, for reducing the fuel consumption of vehicles. | 2010-07-29 |
20100190672 | PRODUCTION OF POLYOL ESTER LUBRICANTS FOR REFRIGERATION SYSTEMS - A poly(neopentylpolyol) ester composition is produced by reacting a neopentylpolyol having the formula: | 2010-07-29 |
20100190673 | ENCAPSULATES - Encapsulates, compositions, packaged products and displays comprising such encapsulates, and processes for making and using such encapsulates, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs. | 2010-07-29 |
20100190674 | ENCAPSULATES - Encapsulates, compositions, packaged products and displays comprising such encapsulates, and processes for making and using such encapsulates, compositions, packaged products and displays. Such compositions have improved deposition and retention properties that may impart improved benefit characteristics to a composition and/or situs. | 2010-07-29 |
20100190675 | Personal Care Article For Sequentially Dispensing Compositions With Variable Concentrations Of Hydrophobic Benefit Materials - The personal care article comprises a single chamber package and a personal care product. The package comprises a dispensing orifice, a first zone, a second zone and a third zone that are located proximal, medial and distal to the dispensing orifice. The personal care product comprises a first, a second and a third personal care composition with a first, second, and third concentration of hydrophobic benefit material. The first, second, and third personal care compositions are substantially within the first, second and third zones. The personal care product comprises a second concentration that is greater than the first and third concentration of hydrophobic benefit material. The personal care product is sequentially dispensed, such that, the first personal care composition is capable of being substantially dispensed prior to the second and third personal care compositions and the second is capable of being substantially dispensed prior to the third personal care composition. | 2010-07-29 |
20100190676 | COMPOSITION FOR ENHANCED REMOVAL OF BLOOD SOILS - A composition for blood-containing soils is provided. The composition is useful in warewashing, hard surface cleaning, laundry, and in cleaning medical, dental, and animal care instruments and implements. A composition of the invention comprises an iron chelant, a reducing agent, and lysing agent. Compositions of the invention may be provided in concentrated form or as ready-to-use solutions and may be provided in liquid, powder, solid, or granulated forms. Optional additional ingredients include but are not limited to surfactants, pH modifiers, viscosity modifiers, water, builders, corrosion inhibitors, threshhold agents, anti-redeposition agents, aesthetic aids, antimicrobial agents, solidification agents, and processing aids. A desirable feature of the invention lies in its ability to clean blood-containing soils at low active concentrations. The invention further provides a method of removing blood-containing soils from a surface including applying a composition to a soil, the composition including an iron sequestrant, a reducing agent, and a lytic agent. | 2010-07-29 |
20100190677 | LAUNDRY MULTI-COMPARTMENT POUCH COMPOSITION - Laundry multi-compartment pouch made from a water-soluble film and having at least two compartments. The pouch of the present invention comprises a composition containing a solid component and a liquid component, wherein the solid component contains a peroxide source and a mixture of specific polymer. | 2010-07-29 |
20100190678 | BLEACH COMPOSITIONS - Laundry or cleaning composition comprising: (a) a catalytically effective amount, preferably from about 1 ppb to about 99.9%, of a transition-metal bleach catalyst which is a complex of a transition-metal and a cross-bridged macropolycyclic ligand; and (b) at least about 0.1% of one or more laundry or cleaning adjunct materials, preferably comprising an oxygen bleaching agent. Preferred compositions are laundry compositions and automatic dishwashing detergents which provide enhanced cleaning/bleaching benefits through the use of such catalysts. | 2010-07-29 |
20100190679 | FABRIC SOFTENING LAUNDRY DETERGENT - Aqueous laundry detergent compositions containing surfactants and fatty acid, having a pH of from about 6 to about 11 and containing a polymer having a number average molecular weight of from about 700,000 to about 4,000,000 and comprising monomeric units including: nonionic monomers selected from acrylamide, N,N-dialkyl acrylamide, methacrylamide, N,N-dialkylmethacrylamide, hydroxyalkyl acrylate and vinyl pyrrolidone, vinyl acetate, vinyl alcohol, and mixtures thereof; cationic monomers selected from N,N-dialkylaminoalkyl methacrylate, N,N-dialkylaminoalkyl acrylate, N,N-dialkylaminoalkyl acrylamide, N,N-dialkylaminoalkylmethacrylamide, methacylamidoalkyl trialkylammonium chloride, acrylamidoalkylltrialkylammonium chloride, vinylamine, quaternized vinyl imidazole and diallyl dialkyl ammonium chloride, and mixtures thereof; and anionic monomers selected from acrylic acid, methacrylic acid, maleic acid, vinyl sulfonic acid, styrene sulfonic acid, acrylamidopropylmethane sulfonic acid (AMPS), salts thereof, and mixtures thereof; in a specified mole ratio. | 2010-07-29 |
20100190680 | Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2010-07-29 |
20100190681 | Alpha-Amylase Mutants with Altered Properties - The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca | 2010-07-29 |
20100190682 | USE OF PROTEIN HYDROLYSATES TO STABILIZE METALLOPROTEASE DETERGENT FORMULATIONS - The present invention provides compositions and formulations comprising metalloprotease enzymes and protein hydrolysate inhibitors that exhibit increased storage stability. In one embodiment, the present invention provides liquid detergent formulations comprising at least one metalloprotease (e.g., | 2010-07-29 |
20100190683 | SOLIDIFIED DETERGENT COMPOSITIONS AND METHOD FOR PRODUCING THE SAME - According to the present invention, a solidified detergent composition is provided. The solidified detergent composition is characterized by having a reduced-pressure dried substance obtained by reduced-pressure drying a solution of (a) a silicon-containing compound with the addition of (b) at least one of surfactant to the silicon-containing compound, or a reduced-pressure dried substance obtained by reduced-pressure drying a solution of (a) a silicon-containing compound and (b) at least one of surfactant added to the resultant reduced-pressure dried substance, the silicon-containing compound being represented by the following general formula (1): | 2010-07-29 |
20100190684 | INHIBITION OF PALMITOYL ACYL TRANSFERASE EXPRESSION AND/OR ACTIVITY FOR THE REGULATION OF ANTIPROLIFERATIVE FACTOR ACTIVITY - The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent. | 2010-07-29 |
20100190685 | PROGNOSTIC FACTOR IN SARCOMA, AND METASTASIS INHIBITOR - The present invention relates to uses of sarcopodin as a gene associated with distant metastasis or prognosis for survival in tumors. Specifically, the present invention provides a method of determining the risk of distant metastasis or prognosis for survival in a tumor, comprising measuring the expression level of sarcopodin in a tumor tissue. Furthermore, the present invention provides an agent for inhibiting metastasis containing a polynucleotide complementary to an mRNA that encodes sarcopodin or an expression vector capable of expressing the polynucleotide. | 2010-07-29 |
20100190686 | NOVEL SECRETED PROTEINS OF ADIPOCYTES FOR DIAGNOSTIC PURPOSES - The present invention relates to the discovery of polypeptide biomarkers excreted into the blood stream (serum or plasma) and/or urine from adipocytes and their use to determine the existence of metabolic syndrome (prediabetic) and/or diabetic conditions (including type 2 diabetes) including insulin resistance and/or glucose intolerance, their use to monitor the state of metabolic syndrome or diabetes toward a state of control and/or cure of the disease state or condition and their use to monitor the long-term health of the patient by determining the existence of metabolic syndrome (prediabetic conditions insulin resistance and/or glucose intolerance) or the existence of type 2 diabetes and to identify potential antidiabetes agents. Methods of identifying potential agents to be used in the treatment of metabolic syndrome and/or type2 diabetes and assays for assisting in the diagnosis of metabolic syndrome and/or type 2 diabetes are additional aspects of the invention. Lipoprotein lipase; Quiescin Q6; Cathepsin B; Complement Component 6; Hippocampal Cholinergic Neurostimulating Protein (HCNP); Serine Protease Inhibitor 2C; Adiponectin; Angiotensinogen (angiotensin); Cyclophilin A; Laminin B1 subunit 1; cartilage glycoprotein 39; complement factor MASP-3 (MASP-3); Niemann-Pick disease, type C2, isoform CRA b (NPC2); Tetranectin; tissue inhibitor of metalloproteinase 2 (TIMP2); Superoxide dismutase secreted; and Spondin 1 | 2010-07-29 |
20100190687 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient. | 2010-07-29 |
20100190688 | Tetrapeptide analogs - Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided. | 2010-07-29 |
20100190689 | COMPOSITIONS AND METHODS RELATED TO PROTEIN DISPLACEMENT THERAPY FOR MYOTONIC DISTROPHY - Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG) | 2010-07-29 |
20100190690 | BIOMIMETIC PARTICLES AND FILMS FOR PATHOGEN CAPTURE AND OTHER USES - The identification and immobilization of glycosylated molecules having biomimetic properties, more particularly naturally-occurring, tissue-derived, non-immunological glycan sequences or functional equivalents thereof, on solid state surfaces and films or on membranes arising at the interface between non-polar and polar materials is described herein. The biomimetic glycosylated films and particles constructed therefrom have industrial, environmental, diagnostic and/or therapeutic utility in the binding, capture, and/or extraction of pathogens, toxins and/or contaminants, in vivo, in vitro or in situ. The present invention further extends to the use of such biomimetic films and particles for the delivery of other therapeutic molecules as well as in the construction of body contacting devices having enhanced biocompatibility and reduced immunogenicity. | 2010-07-29 |
20100190691 | DELIVERY OF NUCLEIC ACIDS USING CELL-PENETRATING PEPTIDES - The present invention is based on the innovative concept of conjugating a cell-penetrating peptide (CPP), including a protein transduction domain, to a nucleic acid molecule to provide a nucleic acid-protein conjugate exhibiting enhanced cellular uptake. Accordingly, the invention provides a method of producing a cell permeable nucleic acid molecule conjugate nucleic acid including a nucleic acid conjugated with a homeodomain of an antennapedia homeotic transcription factor protein (Antp), or functional fragment thereof. The invention further provides compositions and methods treating a subject using the conjugates produced by the method described herein. | 2010-07-29 |
20100190692 | METHODS FOR REDUCING GNRH-POSITIVE TUMOR CELL PROLIFERATION - A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed. | 2010-07-29 |
20100190693 | METHOD FOR SCREENING COMPOUNDS & USES THEREFOR - In accordance with the present invention, it has been discovered that glucose and incretin hormones promote pancreatic islet cell survival via the calcium and cAMP dependent induction, respectively, of the transcription factor CREB. Specifically, a signaling module has been identified which mediates cooperative effects of calcium and cAMP on islet cell gene expression by stimulating the dephosphorylation and nuclear entry of TORC2, a cytoplasmic CREB coactivator. The module comprises a cAMP regulated snfl-like kinase called SIK2 and the calcium regulated phosphatase calcineurin, both of which associate with TORC2 in the cytoplasm. TORC2 is repressed under basal conditions through a phosphorylation dependent interaction with 14-3-3 proteins. cAMP and calcium signals stimulate CREB target gene expression via complementary effects on TORC2 dephosphorylation; cAMP disrupts TORC2-associated activity of SIK2 or related family members, whereas calcium induces TORC2 dephosphorylation via calcineurin. These findings provide a novel mechanism by which CREB activates cellular gene expression, depending on nutrient and energy status, and facilitate development of assays to identify compounds which modulate the role of TORCs. In accordance with the present invention, it has been discovered that fasting and energy-sensing pathways regulate the gluconeogenic program in liver by modulating the nuclear entry of a transcriptional coactivator called Transducer of Regulated CREB Activity 2 (TORC2). Hepatic TORC2 over-expression induces fasting hyperglycemia, whereas knockdown of TORC2 leads to fasting hypoglycemia and silencing of the gluconeogenic program. Since a majority of individuals with Type II diabetes exhibit fasting hyperglycemia due to elevated hepatic gluconeogenesis, compounds that enhance TORC2 phosphorylation will find use as therapeutic agents in this setting. | 2010-07-29 |
20100190694 | Methods for identifying patients who will respond well to cancer treatment - The invention provides methods for identifying patients who will respond well to cancer treatment with a therapeutic regimen that comprises the use of a histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents. The invention also relates to methods of treating such patients with a therapeutic regimen comprising the use of a histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents. | 2010-07-29 |
20100190695 | LIQUID CRYSTAL EMULSION TYPE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE, AND THEREPEUTIC METHOD OF TREATING CUTANEOUS DISEASE THEREWITH - A dermal external pharmaceutical composition that excels in feeling at application or after application and that by enhancing of the transdermal absorption of cyclosporine, exerts medicinal benefits at low concentration. There is provided a liquid crystal emulsion-type pharmaceutical composition comprising cyclosporine, a hydrophilic nonionic surfactant, a lipophilic nonionic surfactant, an oil, a fatty acid that is insoluble in the oil at room temperature, a solid fatty alcohol that is insoluble in the oil at room temperature and a water-soluble polyhydric alcohol that is immiscible with the oil at room temperature, and a method of treating cutaneous diseases with the use of the pharmaceutical composition. | 2010-07-29 |
20100190696 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 2010-07-29 |
20100190697 | UNDERCARBOXYLATED/UNCARBOXYLATED OSTEOCALCIN INCREASES BETA-CELL PROLIFERATION, INSULIN SECRETION, INSULIN SENSITIVITY, GLUCOSE TOLERANCE AND DECREASES FAT MASS - The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity. | 2010-07-29 |
20100190698 | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor - The present invention provides AP-1 signaling inhibitory peptides comprising the amino acid sequences of SEQ ID NOS: 28-31, 36-39, 45-48, 54-57 and 62-65, compositions comprising one or a plurality of said peptides, and methods of treatment of neurological disorders comprising the administration of the peptide(s) or compositions. | 2010-07-29 |
20100190699 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS - Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs. | 2010-07-29 |
20100190700 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS - This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof. | 2010-07-29 |
20100190701 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR). | 2010-07-29 |
20100190702 | Compositions and Methods of Treating Neoplasia - The invention features compositions and methods that are useful for the treatment of neoplasia by reducing base excision repair (BER). Such compositions are useful, for example, for enhancing the efficacy of known chemotherapeutics, such as DNA alkylating agents. In particular, the invention features agents that mimic the interaction of APC with pol-β. Such agents reduce the activity of long patch- and single nucleotide-base extension repair pathways. | 2010-07-29 |
20100190703 | PEPTIDES SPECIFIC FOR HUMAN BLOOD OUTGROWTH ENDOTHELIAL CELLS - Provided herein are compositions and methods for binding outgrowth endothelial cells (OEC). The compositions consist of peptide ligands capable of binding OEC with high affinity and specificity. The compositions of the invention include peptides set forth in SEQ ID NO: 1-38 and variants and derivatives thereof. Compositions also include the nucleotide sequences encoding the peptides of the invention. The compositions find use in methods for the isolation of OEC and for the recruitment and retention of OEC to sites of therapeutic interest. Methods for the identification and isolation of other peptides capable of binding OEC are also provided. | 2010-07-29 |
20100190704 | STRUCTURE COMPRISING CHITOSAN AND COLLAGEN - It is an object of the present invention to provide a structure comprised of a mixture of chitosan and collagen, which achieves both degradability and tissue adhesiveness. The present invention provides a structure comprised of a mixture of chitosan and collagen, wherein (i) the deacetylation degree of chitosan is 50% to 70%, (ii) the weight ratio of chitosan and collagen is 30/70 or more and less than 70/30. | 2010-07-29 |
20100190705 | Suppression of glial fibrillary acidic protein - Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander disease and methods for the identification of such compounds. | 2010-07-29 |
20100190706 | Stable Non-Aqueous Pharmaceutical Compositions - The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent. | 2010-07-29 |
20100190707 | Novel Bacillus Thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2010-07-29 |
20100190708 | Composition for amelioration of body lipid - An object of the present invention is to obtain a composition, which is excellent in amelioration of a lipid metabolism disorder and has a preventive or ameliorating effect on hyperlipemia, obesity or type II diabetes induced by the lipid metabolism disorder, and is also economical and safe with respect to allergy, by extracting a rice bran extract containing a rice bran protein, followed by separation. | 2010-07-29 |
20100190709 | Angiogenic composition - The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic. | 2010-07-29 |
20100190710 | IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention relates to IL-23 receptor antagonists and agonists. The use of IL-23 receptor antagonists in treating autoimmune and inflammatory disorders, as well as methods of identifying IL-23 receptor antagonists and agonists. | 2010-07-29 |
20100190711 | BIG GASTRIN I AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH | 2010-07-29 |
20100190712 | USE OF PEPTIDE YY, ALONE OR IN COMBINATION WITH GLUCAGON-LIKE PEPTIDE, FOR USE IN MEDICINE - The present invention is directed to the use of the peptide compound Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH | 2010-07-29 |
20100190713 | USE OF THE PEPTIDE THYMOSIN BETA 4 ALONE OR IN COMBINATION WITH CECROPIN A AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH or its combination with the peptide Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Asn-Ile-Arg-Asp-Gly-Ile-Ile-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-Lys as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH or its combination optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-07-29 |
20100190714 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 2010-07-29 |
20100190715 | Stable Formulations of Peptides - Method for increasing the shelf-life of a pharmaceutical formulation comprising a glucagon-like peptide. | 2010-07-29 |
20100190716 | USE OF A PLATELET FIBRINOGEN RECEPTOR HEXAPEPTIDE ANTAGONIST AND ALPHA-ENDORPHIN AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound Pro-Ser-Hyp-Gly-Asp-Trp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ser-Hyp-Gly-Asp-Trp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-07-29 |
20100190717 | USE OF MELANIN CONCENTRATING HORMONE AND MET-ENKEPHALIN AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-07-29 |
20100190718 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2010-07-29 |
20100190719 | PEPTIDES AS ANTIMICROBIAL AGENTS TOWARDS CAMPYLOBACTER SPP - The present invention relates to peptides that exhibit antimicrobial properties towards | 2010-07-29 |
20100190720 | Compositions and Methods for Preventing or Treating Cancer - The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer. | 2010-07-29 |
20100190721 | PEPTIDE WHITENING AGENTS AND COSMETIC COMPOSITIONS COMPRISING THE SAME - The present invention relates to novel peptide compounds having the following formula [R | 2010-07-29 |
20100190722 | SUBSTANCE P AND THYROTROPIN RELEASING HORMONE FOR THERAPEUTIC APPLICATIONS - The present invention is directed to the use of the peptide compound Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH | 2010-07-29 |
20100190723 | PREVENTIVE OR THERAPEUTIC COMPOSITION FOR LIVER DISEASE - This invention provides a composition having preventive and/or therapeutic effects on liver disease, which is highly effective, free of side effects, easily ingestible, and capable of long-term ingestion from the viewpoint of a cost and safety. This invention relates to a peptide having the amino acid sequence represented by the following formula: pyroGlu-(X)n-A, wherein X is the same or different and represents Gln or Asn; A represents Gln, Asn, Leu, Ile, or Val; and n is an integer from 0 to 2 or a salt thereof. | 2010-07-29 |
20100190724 | USE OF MELANOCYTE-STIMULATING HORMONE RELEASE-INHIBITING FACTOR AS A THERAPEUTIC AGENT IN THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION - The present invention is directed to the use of the peptide compound Pro-Leu-Gly-NH | 2010-07-29 |
20100190725 | AMINO ACID DERIVATIVES - Compounds of formula (I) or formula (II) have dopaminergic activity: wherein: R | 2010-07-29 |
20100190726 | Novel Phyllanthus Extract - A method is described for producing an extract of | 2010-07-29 |
20100190727 | USE OF MONOSACCHARIDES AND COMPOSITION THEREFOR - The present invention relates to the use, especially the cosmetic use, of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, for reducing or preventing the signs of ageing of the skin or its integuments. The present invention also relates to a cosmetic composition and a device containing it. | 2010-07-29 |
20100190728 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents - Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling. | 2010-07-29 |
20100190729 | Composition for treating atopic dermatitis comprising hirsutanonol or oregonin as an active ingredient - The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13 associated with atopic dermatitis. In addition, hirsutanonol and oregonin increase MBD (mouse beta-defensin)-1, MBD-2 and MBD-3 expression and decrease COX-2 and iNOS expression in mouse animal model of atopic dermatitis. Hirsutanonol and oregonin as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis. | 2010-07-29 |
20100190730 | APPLICATION OF 5-METHYL-1,3-BENZENEDIOL OR DERIVATIVES THEREOF IN THE PREPARATION OF MEDICINES AND FUNCTIONAL FOODS FOR TREATMENT OR PREVENTION OF DEPRESSION - The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine. | 2010-07-29 |
20100190731 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS - The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof. | 2010-07-29 |
20100190732 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY - This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity. | 2010-07-29 |
20100190733 | Methods of Treating Muscular Dystrophies - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group. | 2010-07-29 |
20100190734 | METHOD OF TREATING DRY EYE DISEASE WITH AZITHROMYCIN - The present invention relates to a method for treating dry eye disease. The method comprises identifying a subject suffering from dry eye disease, and administering to the subject an amount of azithromycin effective to reduce dry eye symptoms and/or signs ands to improve tear film quality. Azithromycin is preferably administered topically to the subject in an aqueous ophthalmic solution comprises 0.5-1.5% (w/v) azithromycin in a polymeric suspension. | 2010-07-29 |
20100190735 | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis - An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; and, d) at least one anti-fungal antibiotic agent. A stable nystatin containing formulation is also provided comprising a buffering agent, a preservative, a chelating agent and an anti-oxidant. | 2010-07-29 |
20100190736 | MORPHOLINYL ANTHRACYCLINE DERIVATIVE COMBINED WITH PROTEIN KINASE INHIBITORS - The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) as defined in the specification or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and a protein kinase (PK) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. | 2010-07-29 |
20100190737 | COMPOSITIONS COMPRISING INOSINE AND OROTIC ACID AND METHODS OF USE THEREOF FOR THE TREATMENT OF CERTAIN HEART CONDITIONS AND ENHANCEMENT OF WORK CAPACITY - The invention comprises a composition of inosine and orotic acid or a salt thereof, and its methods of use in treating, maintaining and enhancing the health of the heart, and specifically the integrity of the myocardium. The effective combination of inosine and orotic acid/orotate effectively improves various medical parameters that are widely used to assess cardiac function and structure. These include EKG and VCG recordings, quantitative assessments of work capacity and athletic performance, clinically relevant observations, and direct biochemical, histological and ultrastructural analyses. The observations and controlled studies in mice, rats, rabbits, cardiology patients and high performance human athletes (cyclists) consistently support the effectiveness of the combination of inosine and orotic acid/orotate in both preventing and reversing damage to the myocardium resulting from physical stress. | 2010-07-29 |
20100190738 | Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals - The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. | 2010-07-29 |
20100190739 | Rapidly Dissolving Vitamin Formulation and Methods of Using the Same - Rapidly dissolvable nutritional compositions and methods of providing nutritional supplementation to candidates for, patients undergoing, or patients having undergone bariatric surgery, to patients suffering renal disease, and to candidates for or patients undergoing dialysis. The compositions generally comprise one or more vitamins and optionally minerals and dissolve in less than about 90 seconds upon oral administration. | 2010-07-29 |
20100190740 | OIL-IN-WATER EMULSION - The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5. | 2010-07-29 |